Medicare Bridge Program that will offer GLP-1s to Seniors for $50

[Good-Heart6425]

Medicare GLP-1 Bridge program starts July 2026: what seniors need to know

Medicare GLP-1 Bridge program launches July 1, 2026. Early access to Wegovy, Foundayo, Zepbound KwikPen before full Part D coverage in 2027.

formblends.com

Medicare GLP-1 Bridge program starts July 2026: what seniors need to know​[archived internal link]
Medicare GLP-1 Bridge program launches July 1, 2026. Early access to Wegovy, Foundayo, Zepbound KwikPen before full Part D coverage in 2027.

By FormBlends Editorial Team|Last updated April 16, 2026

Key Takeaway

The Medicare GLP-1 Bridge program begins July 1, 2026, giving eligible Part D beneficiaries early access to Wegovy, Foundayo, and Zepbound KwikPen before full Part D weight-loss coverage arrives January 1, 2027. Zepbound also gets a $50/month cap starting April 2026.

For the first time in Medicare's history, weight-loss GLP-1 medications are about to move from cash-pay territory to covered benefit. The Centers for Medicare and Medicaid Services (CMS) built a phased rollout so seniors dont wait another year for help. If youre on Medicare and youve been priced out of Wegovy or Zepbound, the next nine months change everything.

Here's what the Bridge program does, who it covers, and the moves you should make before July 1.

What is the Medicare GLP-1 Bridge program?​[archived internal link]

The Medicare GLP-1 Bridge is a transitional coverage pathway running from July 1, 2026 through December 31, 2026. It lets eligible Part D beneficiaries fill prescriptions for approved weight-loss GLP-1s at reduced cost-sharing while CMS finalizes formularies for full Part D coverage that starts January 1, 2027.

Until now, Medicare by law couldnt cover drugs prescribed solely for weight loss. That restriction dates to the 2003 Medicare Modernization Act. The Inflation Reduction Act, paired with 2025 CMS rulemaking on obesity as a chronic disease, created the legal pathway. The Bridge exists because CMS didnt want to make 65 million beneficiaries wait six extra months while plan sponsors updated formularies.

Think of it as a pilot with teeth. Plans that opt in get federal reimbursement for covered fills, and beneficiaries get a preview of what 2027 benefits will look like.

Who qualifies for coverage?​[archived internal link]

You qualify for the Bridge if you have active Medicare Part D coverage, a BMI of 30 or higher (or 27+ with at least one weight-related comorbidity like type 2 diabetes, hypertension, or sleep apnea), and a prescription from a Medicare-enrolled prescriber. Plan sponsors will layer prior authorization and step therapy on top of these federal minimums.

The comorbidity list matters. About 71% of Medicare beneficiaries over 65 have at least one qualifying condition, according to CMS chronic-condition data from 2025. That pulls tens of millions of seniors into eligibility even if theyre below the BMI 30 threshold.

Dual-eligible beneficiaries (Medicare plus Medicaid) get an additional pathway through the BALANCE model, which activates in Medicaid opt-in states starting May 2026. BALANCE coordinates coverage so duals dont fall through the cracks between state and federal formularies. If you live in a non-expansion state, coverage flows only through Part D.

Medicare Advantage enrollees are included. Your MA-PD plan must cover at least one GLP-1 from the CMS-approved list, though the specific drug and tier placement vary by plan.

Which GLP-1 medications are covered?​[archived internal link]

The Bridge covers three medications: Wegovy (semaglutide injectable), Foundayo (orforglipron, the oral once-daily pill from Eli Lilly), and Zepbound KwikPen (tirzepatide in a multi-dose pen device). Ozempic and Mounjaro remain covered only for type 2 diabetes, since theyre not FDA-approved for weight loss

Zepbound KwikPen, approved in early 2026, replaces the single-use auto-injectors with a reusable pen that holds four doses. CMS negotiated the KwikPen specifically because it reduced per-dose manufacturing cost and let Lilly accept the $50/month price cap.

Not covered under the Bridge: compounded semaglutide or tirzepatide, Saxenda (liraglutide), and any off-label GLP-1 use. If your current prescription is compounded, youll need to transition to brand before July 1 to use Bridge benefits.

How does the $50/mo Zepbound cap work?​[archived internal link]
Starting April 1, 2026, Eli Lilly caps out-of-pocket cost for Zepbound at $50 per month for Medicare Part D beneficiaries, whether or not the Bridge program has activated yet. The cap applies at the pharmacy counter through a manufacturer copay assistance program that works alongside Part D benefits.

Before this cap, Medicare patients paid $900 to $1,600 per month out of pocket for Zepbound since Part D excluded weight-loss coverage. The cap is Lilly's response to competitive pressure from Novo Nordisks Wegovy pricing and the Inflation Reduction Act negotiation framework. Its not charity, its market positioning ahead of 2027 formulary placement.

The mechanics: your pharmacy runs your Part D claim first, then the Lilly assistance program covers remaining out-of-pocket up to the $50 cap. You show your Medicare card and the Zepbound savings card (available at zepbound.com or through your prescriber). No income cap applies on the Bridge-era version of the program.

Wegovy hasnt matched the $50 number yet. Novo Nordisk currently offers a $199/month cash pay program for Medicare patients ineligible for coverage, with formal cap announcements expected before July. Compare current pricing in our Ozempic and GLP-1 cost guide for 2026.

What happens between July 2026 and January 2027?​[archived internal link]
The Bridge period is a six-month preview window. Part D plans that opt in start covering eligible GLP-1 fills July 1, with standard tier cost-sharing (typically Tier 3 or Tier 4 preferred brand). Plans not opting in direct beneficiaries to manufacturer assistance programs and existing cash-pay channels.

CMS estimates 78% of standalone Part D plans and 85% of MA-PD plans will opt in, based on preliminary bid data submitted in June 2025. That leaves a coverage gap for beneficiaries in non-participating plans, mostly regional or low-premium plans that couldnt absorb the cost without premium increases.

Here's the timeline you need to track

What should Medicare patients do right now?​[archived internal link]
Start with three moves before July. First, get a documented BMI and comorbidity record from your primary care provider. Bridge eligibility hinges on chart documentation, not self-report. If your last weight check was more than six months ago, schedule one. Second, pull your current Part D plan's preliminary 2026 formulary update, which most plans publish mid-April. Confirm whether your plan is opting into the Bridge.

Third, decide your drug preference now. If you want Wegovy, youre on a weekly injection pathway. If Zepbound KwikPen fits your budget better with the $50 cap, youll need a prescriber willing to write it. If Foundayo appeals because its oral, confirm your plan covers it, since some plans initially tiered orforglipron higher than injectables.

For the 81% of large employer plans that still dont cover GLP-1s for weight loss (based on Mercer 2026 data), Medicare beneficiaries coming off employer plans at 65 are actually better positioned under the new Bridge than their still-working peers. Thats a weird inversion of how coverage usually works.

If you dont qualify for the Bridge or your plan opts out, telehealth cash-pay channels remain available. FormBlends compares covered and uncovered pathways in our 2026 State of GLP-1 Telehealth report, and our no-insurance weight-loss guide walks through options when Medicare or employer coverage isnt available.

Ready to talk to a licensed prescriber about GLP-1 options? Start your consultation or browse the FormBlends provider directory to find clinicians who work with Medicare patients.

Frequently asked questions​[archived internal link]
Will Original Medicare (Parts A and B) cover GLP-1s for weight loss?​[archived internal link]
No. Weight-loss GLP-1 coverage flows exclusively through Part D and Medicare Advantage Prescription Drug (MA-PD) plans. Part B still doesnt cover outpatient prescription drugs for obesity. If you only have Parts A and B, youll need to enroll in a standalone Part D plan during Open Enrollment to access Bridge benefits

 

[Rolltide61]

What insurance or this program does not address is maintenance. Once goal weight is achieved there has to be a maintenance dose covered. If they don't then people just end up here buying from the grey market.

 

[RubbaDubba1]

I'm waiting for this to hit, so mom can try the pills at a reasonable price. Shots didn't go to well

 

[Dr Pepperspray]

Interesting. I hope it will be better soon!

 

[krsct]

Any insight on what "full Part D coverage" will look like?

 

[Calm Logic]

What insurance or this program does not address is maintenance. Once goal weight is achieved there has to be a maintenance dose covered. If they don't then people just end up here buying from the grey market.

The Bridge program does cover maintenance, including people with a normal BMI, provided they met the inclusion criteria whenever they first started a GLP-1.

 

[Atlanatpr]

I’m so excited for this. Some states also have early access my own state does for example

 

[fatty33]

my sister is over weight and is retired but she said that she is not eligible for Part D because she has too much money. So apparently she is not going to get that price.

 

[Grogu]

my sister is over weight and is retired but she said that she is not eligible for Part D because she has too much money. So apparently she is not going to get that price.

I’m not sure who told your sister that she has too much money to be eligible for Part D, but Part D is actually available to all Medicare beneficiaries regardless of income, but there is an income related component to the monthly fee if the beneficiary’s income is too high, but even those additional monthly premiums are not too onerous. There is no asset test, so she can’t have too many assets to qualify. But if she makes that much money and has that many assets, that she could probably afford the Lilly Direct rate.

 

[Looming Sharq 51680]

The Bridge program does cover maintenance, including people with a normal BMI, provided they met the inclusion criteria whenever they first started a GLP-1

The Bridge program does cover maintenance, including people with a normal BMI, provided they met the inclusion criteria whenever they first started a GLP-1

The Bridge program does cover maintenance, including people with a normal BMI, provided they met the inclusion criteria whenever they first started a GLP-1.

I read that if you started taking glp-1 at a BMI of 35 or higher they will cover a maintenance dose.

 

[Wellwell]

I'm already seeing talk of the states trying to pull out of this. They say they will go broke trying to support it.

 

[Calm Logic]

I read that if you started taking glp-1 at a BMI of 35 or higher they will cover a maintenance dose.

Or at lower BMIs with a condition like high blood pressure (BMI 30+), prediabetes (BMI 27+), etc:

FDA cracks down on ‘misleading’ compounded GLP-1s by telehealth companies

You know what's misleading? Articles like this. I know the compounding pharmacies are just in it for the money, but they aren't lying when they say they have the same active ingredient as Ozempic or Zepbound. It's quite a leap to equate this to "FDA Approved". "FDA Approved" does not mean...

glp1forum.com

 

[HumanusExMachina]

Any insight on what "full Part D coverage" will look like?

I have full Part D. It costs me $15 a month (comes out of my SS). Since I'm also still employed, I also pay a "penalty" of $8 a month. It covers all my normal prescriptions -- pretty much the same as your average medical insurance's drug coverage.

 

[Looming Sharq 51680]

Or at lower BMIs with a condition like high blood pressure (BMI 30+), prediabetes (BMI 27+), etc:

FDA cracks down on ‘misleading’ compounded GLP-1s by telehealth companies

You know what's misleading? Articles like this. I know the compounding pharmacies are just in it for the money, but they aren't lying when they say they have the same active ingredient as Ozempic or Zepbound. It's quite a leap to equate this to "FDA Approved". "FDA Approved" does not mean...

glp1forum.com

I don't have any conditions. I'm going to give it a try anyways!

 

[BNLFL]

my sister is over weight and is retired but she said that she is not eligible for Part D because she has too much money. So apparently she is not going to get that price.

Wrong. I made a shitload of money working, and medicare jacked me hard on D. The D part is were they can get you. You need a supplement.

I’m not sure who told your sister that she has too much money to be eligible for Part D, but Part D is actually available to all Medicare beneficiaries regardless of income, but there is an income related component to the monthly fee if the beneficiary’s income is too high, but even those additional monthly premiums are not too onerous. There is no asset test, so she can’t have too many assets to qualify. But if she makes that much money and has that many assets, that she could probably afford the Lilly Direct rate.

My wife and I were getting jacked medicare due to the money I had made working. We were paying $587.90 compared to the standard $202.90 a month. Don't forget the supplement for hospital stay and stuff. This is crap nobody told me about when I was retiring. Thanks to a worker in the SS office, he caught my outrageous amount and told me how to fix it. I only went into the SS office to check when I actually signed to start getting my benefits. Saving $770/month for the two of us.

 

[Atlanatpr]

I'm already seeing talk of the states trying to pull out of this. They say they will go broke trying to support it.

States can’t pull out. It’s a federal program

 

[Good-Heart6425]

A Guide to Medicare’s New Coverage for Obesity Drugs NYT May 15, 2026

What you should know about the federal government’s pilot program offering GLP-1s solely for weight loss. Listen · 9:21 min

The list of GLP-1s that can be prescribed for obesity includes Eli Lilly’s Foundayo, Wegovy in injectable and tablet forms, and Eli Lilly’s Zepbound KwikPen.Credit...Hannah Beier/Reuters

By Mark Miller

May 15, 2026 Millions of older Americans may have access for the first time to obesity drugs at a low price of $50 a month starting in July under a Medicare pilot program.

While Medicare Part D already covers some GLP-1 medications for conditions like diabetes, cardiovascular disease and sleep apnea, the government program for people 65 and older had prohibited coverage solely for obesity. Now, more people on Medicare will be eligible, including those who are most overweight and those with both obesity and conditions like prediabetes or uncontrolled hypertension.

The $50 monthly price — which will cover any dosage amount — is much lower than what Medicare patients currently pay out of pocket for GLP-1s.

About 40 percent of the 70 million people enrolled in Medicare meet the clinical definition of obesity, data from the Centers for Disease Control and Prevention shows. The Congressional Budget Office estimates that 29 million Medicare beneficiaries would then qualify for GLP-1 drug coverage, although 16 million already have access for conditions such as diabetes or cardiovascular disease.

But many older people may not be able to afford an extra $600 a year for another prescription, as they are already struggling with rising health care costs. KFF, a health research organization, reported that one in four Medicare beneficiaries had an income below $24,600 in 2024, and that half lived on incomes below $43,200.

Another concern is whether the program would extend beyond 2027. Although the pilot could be continued, adding the benefit permanently would require a change in federal law and agreement among health insurance companies to offer the medications in Part D prescription drug plans.

The financial burden for Medicare is another consideration if such coverage were extended. The C.B.O. estimated that adding weight-loss drugs would cost Medicare $35 billion from 2026 to 2034. A spokesperson for the Centers for Medicare and Medicaid indicated that the agency had not publicly released cost estimates on either the pilot, called the Medicare GLP-1 Bridge program, or the permanent model.Here is what Medicare beneficiaries seeking coverage need to know about the pilot program.

Who can participate? Those eligible include not only enrollees who are 65 and older but also Medicare beneficiaries with disabilities.

The Bridge program is temporary, open mainly to people already enrolled in either the Part D prescription plan or the private Medicare Advantage plans that include drug coverage. But your Part D provider will not offer coverage.

“Your Part D plan will have nothing to do with making decisions about whether or not you can access a GLP-1 under the Bridge model,” said Juliette Cubanski, deputy director of the program on Medicare policy at KFF.

Instead, a health care provider must determine whether you meet the Bridge program’s clinical requirements, which are based on body weight and health status. Patients with a body mass index of 35 or higher will qualify; those with a lower B.M.I. may also qualify if they have been diagnosed with other related conditions.

Providers will need to submit a prior authorization request and a prescription to Humana, which will be processing requests.

If the request is approved, you can fill the prescription at any pharmacy. The list of GLP-1s that can be prescribed for obesity includes Eli Lilly’s Foundayo and Novo Nordisk’s Wegovy in injectable and tablet forms; and Lilly’s Zepbound KwikPen.

If you are taking a GLP-1 drug for a different condition, such as diabetes, that will continue to be covered by your Part D plan.

What will this cost? The $50-a-month co-pay is separate from any premiums or deductibles you pay for Part D. Because Bridge purchases are processed outside Part D, the monthly cost does not count toward Part D deductibles or out-of-pocket spending limits.

Older people with very low incomes typically qualify for assistance with Part D costs through a federal program called Extra Help, which subsidizes premiums, deductibles and cost sharing. That assistance will not be available because the program runs outside Part D.

Those who have both Medicare and Medicaid coverage and are not required to make co-payments — or minimal ones at most — would be eligible. But the $50-a-month price would apply to them, too.

“It could be difficult for low-income and modest-income older adults to participate and take advantage of the new coverage,” said Ramsey Alwin, chief executive of the National Council on Aging.

State Medicaid programs already have the option of covering GLP-1 drugs for obesity treatment, but only about a dozen states do so, according to KFF.

Why is this outside Part D? Federal law prohibits Medicare from covering medications prescribed specifically for weight loss; making GLP-1 coverage permanent would require an act by Congress. In the meantime, C.M.S. has the legal authority to run time-limited “demonstration projects” to test new payment or coverage approaches like this one.

The federal government had aimed to move the weight-loss drug coverage from its pilot to Part D in 2027. But health insurance companies balked because of the potentially high costs of covering enrollees and a lack of data for determining the number of patients that would guide their pricing plans next year, said Kylie Stengel, principal at Avalere Health, a research and consulting company.

“There’s really no historical data on GLP-1 use for obesity in Medicare, and insurance plans really need that data to assess that risk so that they can accurately set plan prices,” she said.

Will I still be able to get the drugs after the pilot ends? It is an important question, because research shows that most people need to stay on the drugs to maintain weight loss or other health benefits. There is no clarity on next steps, Dr. Cubanski of KFF said. Much will depend on whether C.M.S. can persuade more insurance plans to participate.

“The really big question is what happens at the end of 2027 if C.M.S. isn’t able to stand up this model in Part D,” she said.

Even if Part D does permanently cover the GLP-1s for weight loss, some people will not be able to afford the drugs. Cost-sharing is expected to increase above the pilot’s monthly fee of $50.

One recent University of Pennsylvania study found that monthly cost-sharing for GLP-1 drugs already covered by Part D ran as high as an estimated $167 a month last year.

“I’d expect similar costs for the weight-loss drugs, and maybe higher,” said Matthew Klebanoff, an assistant professor of medicine at the University of Pennsylvania and an author of the study.

Polling by KFF found that over half of GLP-1 users said these drugs were difficult to afford, and one in four said they were “very difficult” to afford.

The price of these drugs makes forecasting uncertain. Drug manufacturers agreed to supply the weight-loss drugs to Medicare enrollees at a net price of $245 a month — a steep discount compared with prices in commercial markets.

Also uncertain is how much Medicare might save over time, when taking into account the potential for reductions in obesity-related health conditions, including metabolic, cardiovascular and respiratory illnesses. The C.B.O. estimate included $3 billion in savings over that period — but that figure may be conservative.

One group of researchers projected savings of $18 billion over a 10-year period. “We found large downstream reductions in the rates of diabetes and cardiovascular disease, in particular,” said Elbert Huang, a professor of medicine at the University of Chicago and co-author of the study.

The affordability issue — coupled with uncertainty about whether the pilot will lead to permanent coverage under Part D — worried some experts. Millions of older people might start GLP-1 treatment for obesity but then be suddenly cut off.

“There’s a great deal of concern about people having yo-yo experiences with GLP-1 drugs,” Dr. Huang said. “When people stop treatment, they not only regain the weight they had lost — but the weight they put back on is predominantly fat.” “We’re about to do a giant national experiment on older adults in America,” he added.

 

[Tirzmonkey]

The requirements to be covered are just as onerous as other insurance. Most won’t qualify.